Skip to main content


Figure 1 | Cost Effectiveness and Resource Allocation

Figure 1

From: Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

Figure 1

Model diagram. A cost-effectiveness model was constructed according to the changes in NYHA class from baseline to 24 weeks in the placebo and FCM groups. The key assumptions of the model were as follows: 1) the effect of the intervention was immediate and lasted throughout 24 weeks in the placebo and FCM groups, and 2) no difference in safety was observed between the 2 groups.

Back to article page